DARE | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 15%

Liquidity 42%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-20.91%

1 Month

65.69%

3 Months

16.41%

6 Months

8.61%

1 Year

-24.58%

2 Year

663.54%

Key data

Stock price

$2.27

P/E Ratio

N/A

DAY RANGE

$2.15 - $2.50

EPS

-$1.39

52 WEEK RANGE

$1.27 - $9.19

52 WEEK CHANGE

-$24.33

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

14.560 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

2.17

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,000,363

AVERAGE 30 VOLUME

$839,311

Company detail

CEO: Sabrina M. Johnson
Region: US
Website: darebioscience.com
Employees: 30
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Daré Bioscience, Inc. develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive.

DARE - Dare Bioscience, Inc.